ArticleInflammopharmacology2025
Chloroquine protects against mesenteric ischemia: insights into the role of nitrergic and opioidergic systems.
Article in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exogenous phosphatidylserine protects against mesenteric ischemia-reperfusion with associated Akt/mTOR pathway upregulation.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute mesenteric ischemia is a severe condition with high mortality and no established pharmacological treatment, driven by oxidative stress, inflammation, and microvascular dysfunction. Chloroquine, an immunomodulatory agent, has shown protective effects in ischemic models, but its role in mesenteric ischemia and its interaction with regulatory pathways remain unclear.
objectiveTo evaluate protective effects of chloroquine in mesenteric ischemia and its interaction with the nitrergic and opioidergic systems.
methodsEighty-four male Wistar rats were randomly assigned to fourteen groups and subjected to sixty minutes of mesenteric artery occlusion, followed by sixty minutes of reperfusion. Chloroquine (1-10 mg/kg) was administered, with the minimal effective dose (5 mg/kg) combined with a nitric oxide synthase inhibitor, a nitric oxide precursor, or an opioid receptor antagonist or agonist. Histopathological assessments and biochemical analyses of oxidative and inflammatory markers were conducted.
resultsChloroquine at 5 and 10 mg/kg significantly reduced histopathological scores, with the 5 mg/kg dose associated with increased glutathione and reduced malondialdehyde, myeloperoxidase, tumor necrosis factor-alpha, interleukin-6, and nuclear factor kappa B levels. The opioidergic system contributed to antioxidant effects, enhancing reductions in malondialdehyde and nitric oxide levels, while increasing glutathione levels. In contrast, its anti-inflammatory properties were influenced by the nitrergic pathway, as indicated by increased nuclear factor kappa B levels and histopathological scores upon N(ω)-nitro-L-arginine methyl administration.
conclusionChloroquine protects against mesenteric ischemia by modulating oxidative and inflammatory pathways, with the opioidergic and nitrergic systems mediating its effects. These findings highlight a potential therapeutic role for chloroquine, warranting further investigation.
Indexed as
Identifiers
41047444What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.